Health Canada approves obesity drug Wegovy

Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese website Yicai. However, patients in China will have to pay out of pocket for the treatment, as it is not yet covered by the national healthcare insurance, João da Silva of BBC reported.
Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults
Novo Nordisk launches obesity drug Wegovy in China
Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Health Matters: Wegovy approved to reduce heart attack risk
Novo Nordisk says Health Canada has approved its weight loss drug Wegovy to reduce the risk of heart attacks in some adults. Kyle Benning has the details and more in Health Matters for Nov. 27, 2024.
The Economist8h
Wegovy hits the People’s Republic, at last
But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...
Wegovy costs $1,349 in the US vs. $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...
Wall Street Journal on MSN2d
Novo Nordisk Says White House Obesity Plan Is Step in Right Direction
The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Bloomberg L.P.3d
Novo Nordisk Foundation Targets US, Europe After Obesity Boost
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk sells hit weight-loss drug in China—at fraction of US price
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Benzinga.com10d
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ...
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...